Nutri Metab Cardiovas:降低心衰风险、延长心血管疾病患者寿命,间歇性禁食益处多多!

2019-11-19 Paris 转化医学网

导语:间歇性禁食最初因“网红减肥法”而被大家所熟知,近些年更因为其可改善类风湿性关节炎、多发性硬化症以及糖尿病患者的病情而备受热议。

导语:间歇性禁食最初因“网红减肥法”而被大家所熟知,近些年更因为其可改善类风湿性关节炎、多发性硬化症以及糖尿病患者的病情而备受热议。



11月16日在费城举行的美国心脏协会(AHA)的科学年会上,发布了一篇关于间歇性禁食(IF)的研究新进展。研究指出:在调整相关因素后,与未进行IF的人群相比,间歇性禁食的人,患心衰(HF)的风险显著下降了71%;不仅如此,生存期也相对延长。

该研究由盐湖城山间保健心脏研究所的研究人员进行,共纳入近2000名心血管疾病患者,包括1568名非禁食者和389名禁食者,并对他们进行了4.4年的追踪。为了排除其他因素的干扰,研究人员同时评估了其他参数,包括人口统计学、社会经济因素、心脏危险因素、共病诊断、药物和治疗,以及其他生活方式行为(如吸烟、喝酒等)。

结果显示:与未曾进行间歇性禁食的患者相比,采用IF饮食法的患者表现出了更好的生存率和更低的心衰风险,具体而言,其发生心肌梗死的风险下降了31%(HR= 0.69, 95% CI:0.44-1.09)。


 间歇性禁食对心衰风险及心梗风险的影响

间歇性禁食为什么会有如此“神奇”的功效呢?其背后的机制目前尚不得而知,但从现有研究来看,禁食期间由于血液中的营养成分较少,毒性应激激素浓度较高,这些免疫细胞会“躲”到富含营养物质的骨髓隔室中保持存活。并且,这样的一次“诺曼底登陆”不仅没有让其损兵折将,反而帮助它们进化成更强的免疫能力,帮助人体抵抗病毒,进而帮助人们延长生存期。

另一方面,霍恩博士此前曾对间歇性禁食影响糖尿病和冠心病患者的风险进行过研究,发现常规间歇禁食的患者患病率较低。霍恩博士表示:禁食影响人的血红蛋白、红细胞计数、人类生长激素的水平,降低钠离子和碳酸氢盐的水平,同时也激活酮症和自噬,诸多影响带来的连锁反应最终降低了心力衰竭和冠心病的风险。

间歇性禁食不同于常规的禁食,是指限制某个时间段内的食物摄入。可以是每周禁食一天或每月禁食一天,但并不是连着几天禁食。实际上,由于宗教或精神方面的原因,包括伊斯兰教,基督教,犹太教和佛教,经常通过此种方式来净化提升自己。

霍恩博士指出,通常需要12小时以上的禁食才能达到实验效果,该研究也并未明确禁食带来的心理影响,间歇性禁食并不适合所有人,尤其孕妇和哺乳期妇女以及年幼的儿童和体弱的老年人。当然,接受器官移植、免疫系统受到抑制以及正在经历急性或严重的慢性感染的患者也不应该禁食。

即便有诸多研究佐证,间歇性禁食所带来的各种益处要么在动物实验中得到验证,要么在医护人员的密切监护下得到体现,归根究底,还是要权衡利弊,切不可盲目跟风。

原始出处:

Parvin Mirmirana, Zahra Bahadoranb,Bahadoran, Zahra Gaeinib, et.al. Effects of Ramadan intermittent fasting on lipid and lipoprotein parameters: An updated meta-analysis. NMCD September 2019 Volume 29, Issue 9, Pages 906–915

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1799099, encodeId=fe151e990996c, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jul 22 03:44:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955024, encodeId=5b5a1955024a5, content=<a href='/topic/show?id=732f9e265d7' target=_blank style='color:#2F92EE;'>#间歇性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97265, encryptionId=732f9e265d7, topicName=间歇性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0361487, createdName=花花1366, createdTime=Sun May 17 22:44:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888091, encodeId=4d1118880915d, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Aug 20 02:44:00 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896581, encodeId=2ceb1896581cb, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jul 01 02:44:00 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389465, encodeId=580d1389465be, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Nov 21 04:44:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498653, encodeId=7cb61498653c0, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Nov 21 04:44:00 CST 2019, time=2019-11-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1799099, encodeId=fe151e990996c, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jul 22 03:44:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955024, encodeId=5b5a1955024a5, content=<a href='/topic/show?id=732f9e265d7' target=_blank style='color:#2F92EE;'>#间歇性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97265, encryptionId=732f9e265d7, topicName=间歇性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0361487, createdName=花花1366, createdTime=Sun May 17 22:44:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888091, encodeId=4d1118880915d, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Aug 20 02:44:00 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896581, encodeId=2ceb1896581cb, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jul 01 02:44:00 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389465, encodeId=580d1389465be, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Nov 21 04:44:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498653, encodeId=7cb61498653c0, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Nov 21 04:44:00 CST 2019, time=2019-11-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1799099, encodeId=fe151e990996c, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jul 22 03:44:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955024, encodeId=5b5a1955024a5, content=<a href='/topic/show?id=732f9e265d7' target=_blank style='color:#2F92EE;'>#间歇性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97265, encryptionId=732f9e265d7, topicName=间歇性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0361487, createdName=花花1366, createdTime=Sun May 17 22:44:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888091, encodeId=4d1118880915d, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Aug 20 02:44:00 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896581, encodeId=2ceb1896581cb, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jul 01 02:44:00 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389465, encodeId=580d1389465be, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Nov 21 04:44:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498653, encodeId=7cb61498653c0, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Nov 21 04:44:00 CST 2019, time=2019-11-21, status=1, ipAttribution=)]
    2020-08-20 guojianrong
  4. [GetPortalCommentsPageByObjectIdResponse(id=1799099, encodeId=fe151e990996c, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jul 22 03:44:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955024, encodeId=5b5a1955024a5, content=<a href='/topic/show?id=732f9e265d7' target=_blank style='color:#2F92EE;'>#间歇性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97265, encryptionId=732f9e265d7, topicName=间歇性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0361487, createdName=花花1366, createdTime=Sun May 17 22:44:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888091, encodeId=4d1118880915d, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Aug 20 02:44:00 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896581, encodeId=2ceb1896581cb, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jul 01 02:44:00 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389465, encodeId=580d1389465be, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Nov 21 04:44:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498653, encodeId=7cb61498653c0, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Nov 21 04:44:00 CST 2019, time=2019-11-21, status=1, ipAttribution=)]
    2020-07-01 一闲
  5. [GetPortalCommentsPageByObjectIdResponse(id=1799099, encodeId=fe151e990996c, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jul 22 03:44:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955024, encodeId=5b5a1955024a5, content=<a href='/topic/show?id=732f9e265d7' target=_blank style='color:#2F92EE;'>#间歇性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97265, encryptionId=732f9e265d7, topicName=间歇性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0361487, createdName=花花1366, createdTime=Sun May 17 22:44:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888091, encodeId=4d1118880915d, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Aug 20 02:44:00 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896581, encodeId=2ceb1896581cb, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jul 01 02:44:00 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389465, encodeId=580d1389465be, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Nov 21 04:44:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498653, encodeId=7cb61498653c0, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Nov 21 04:44:00 CST 2019, time=2019-11-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1799099, encodeId=fe151e990996c, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed Jul 22 03:44:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955024, encodeId=5b5a1955024a5, content=<a href='/topic/show?id=732f9e265d7' target=_blank style='color:#2F92EE;'>#间歇性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97265, encryptionId=732f9e265d7, topicName=间歇性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0361487, createdName=花花1366, createdTime=Sun May 17 22:44:00 CST 2020, time=2020-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888091, encodeId=4d1118880915d, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Aug 20 02:44:00 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896581, encodeId=2ceb1896581cb, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jul 01 02:44:00 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389465, encodeId=580d1389465be, content=<a href='/topic/show?id=8425519625e' target=_blank style='color:#2F92EE;'>#心衰风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51962, encryptionId=8425519625e, topicName=心衰风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Nov 21 04:44:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498653, encodeId=7cb61498653c0, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Thu Nov 21 04:44:00 CST 2019, time=2019-11-21, status=1, ipAttribution=)]

相关资讯

JACC:造影前做心脏磁共振是诊断心梗的新策略

非ST段抬高型心梗伴高敏肌钙蛋白水平升高的患者常规会接受有创的冠脉造影(ICA)检查,但经常会没有冠脉梗阻。本研究的目的旨在评估心脏磁共振(CMR)和计算机断层血管造影(CTA)是否可能成为ICA前的筛选手段。本次随机对照临床试验纳入分析了207名急性胸痛、高敏肌钙蛋白T升高(>14 ng/l)且超声心动图没有确诊的患者(平均年龄64岁,男性占62%)。当初始的CMR或CTA提示为心肌缺血、

Heart:严重三尖瓣反流伴充血性心衰患者的预后分析

部分严重三尖瓣反流(TR)和充血性心衰(CHF)是接受药物治疗,而非手术治疗。本研究目的旨在比较和评估接受三尖瓣手术(TVS)和没有接受手术患者的临床特征和预后。本研究回顾分析了数据库中2556名严重TR患者,并排除接受心脏移植和没有充血性心衰的患者。最终,共纳入分析了534名严重TR和CHF患者,仅55名患者接受了TVS治疗。在479名没有接受手术治疗的患者中,有30%有手术指征。经过38个月的

JACC:影响轻中度主动脉反流患者的自然病程的因素研究

B期主动脉反流(AR)的自然发展病程尚不清楚。本研究的目的旨在评估AR进展的决定因素、速率和后果。本研究纳入分析了1077名≤中度慢性AR的患者(平均年龄66 ± 15),有196名(18%)患者存在基线水平的轻度AR,465名(43%)患者存在轻-中度AR,416名(39%)患者存在中度AR,进展为中重度AR(C/D期)的10年发生率分别为12%, 30%和53%。经过平均4.1年时间的随访,有

盘点:JACC十一月第三期研究一览

1. 重复心脏磁共振对急性心梗患者预后价值研究DOI: 10.1016/j.jacc.2019.08.1061http://www.onlinejacc.org/content/74/20?current-issue=y心脏磁共振(CMR)被广泛应用在急性心梗(AM)的诊断上,CMR常会在6个月后复查一次以评估心梗的进展情况。然而,6个月CMR的临床和预后作用尚不清楚。本研究纳入分析了ITAM

AHA 2019丨COLCOT试验:COLchicine心血管结局试验

2019年11月16日,一年一度的美国心脏协会科学年会(AHA)在美国宾夕法尼亚州费城隆重启幕,来自世界各地的15000多名顶尖医生、科学家、心脏病专家、保健专业人员和其他人士参加本次会议,讨论心血管科学和医学的未来。来自加拿大蒙特利尔心脏研究所的Jean-Claude Tardif教授在第一场LBS专场中为大家揭晓了COLCOT试验的最新研究结果,COLCOT试验的结果将确定,用小剂量消炎药秋水

Eur Heart J:Alirocumab对急性冠脉综合征患者心血管预后的影响

由此可见,在新近的ACS患者中,Alirocumab可改善患者结局,且与年龄无关。这表明降低LDL-C是ACS老年患者重要的预防干预措施。